Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 16, 2021; 9(2): 321-333
Published online Jan 16, 2021. doi: 10.12998/wjcc.v9.i2.321
Gut microbiota and inflammatory bowel disease: The current status and perspectives
Lie Zheng, Xin-Li Wen
Lie Zheng, Xin-Li Wen, Department of Gastroenterology, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi’an 730000, Shaanxi Province, China
Author contributions: Zheng L wrote and revised the manuscript; Zheng L and Wen XL designed the work and supervised preparation of the manuscript.
Supported by Shaanxi Province Natural Science Basic Research Program-general Project, No. 2019JM-580; Project of Shaanxi Administration of Traditional Chinese Medicine, No. 2019-ZZ-JC0010; and Shaanxi Provincial Hospital of Traditional Chinese Medicine, No. 2018-04.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Xin-Li Wen, Director, Professor, Department of Gastroenterology, Shaanxi Provincial Hospital of Traditional Chinese Medicine, No. 4 Xihuamen, Xi’an 730000, Shaanxi Province, China.
Received: October 18, 2020
Peer-review started: October 18, 2020
First decision: November 20, 2020
Revised: November 20, 2020
Accepted: December 6, 2020
Article in press: December 6, 2020
Published online: January 16, 2021
Core Tip

Core Tip: Inflammatory bowel disease (IBD) is a chronic immune-mediated disease that affects the gastrointestinal tract. Researchers have proved that some factors can alter the microbiome and the pathogenesis of IBD. These include mutations in genes involved in microbiome-immune interactions and microbiota-modulating risk factors such as antibiotic use, cigarette smoking, levels of sanitation, and diet. As a result, there has been increasing interest in the application of probiotics, prebiotics, antibiotics, fecal microbiota transplantation, and gene manipulation in treating IBD because of the possible curative effect of these microbiome-modulating interventions.